|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DHX29 |
Gene summary for DHX29 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DHX29 | Gene ID | 54505 |
| Gene name | DExH-box helicase 29 | |
| Gene Alias | DDX29 | |
| Cytomap | 5q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0001731 | UniProtAcc | Q7Z478 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54505 | DHX29 | C30 | Human | Oral cavity | OSCC | 2.26e-35 | 1.54e+00 | 0.3055 |
| 54505 | DHX29 | C38 | Human | Oral cavity | OSCC | 7.06e-12 | 1.27e+00 | 0.172 |
| 54505 | DHX29 | C43 | Human | Oral cavity | OSCC | 2.45e-21 | 4.95e-01 | 0.1704 |
| 54505 | DHX29 | C46 | Human | Oral cavity | OSCC | 2.66e-17 | 5.36e-01 | 0.1673 |
| 54505 | DHX29 | C51 | Human | Oral cavity | OSCC | 2.81e-15 | 8.05e-01 | 0.2674 |
| 54505 | DHX29 | C57 | Human | Oral cavity | OSCC | 6.53e-04 | 3.65e-01 | 0.1679 |
| 54505 | DHX29 | C06 | Human | Oral cavity | OSCC | 5.49e-03 | 9.51e-01 | 0.2699 |
| 54505 | DHX29 | C08 | Human | Oral cavity | OSCC | 8.27e-30 | 6.08e-01 | 0.1919 |
| 54505 | DHX29 | C09 | Human | Oral cavity | OSCC | 4.95e-11 | 4.35e-01 | 0.1431 |
| 54505 | DHX29 | LN38 | Human | Oral cavity | OSCC | 7.50e-04 | 9.63e-01 | 0.168 |
| 54505 | DHX29 | LN46 | Human | Oral cavity | OSCC | 1.44e-06 | 4.92e-01 | 0.1666 |
| 54505 | DHX29 | SYSMH1 | Human | Oral cavity | OSCC | 1.97e-03 | 1.88e-01 | 0.1127 |
| 54505 | DHX29 | SYSMH2 | Human | Oral cavity | OSCC | 7.40e-24 | 7.95e-01 | 0.2326 |
| 54505 | DHX29 | SYSMH3 | Human | Oral cavity | OSCC | 2.35e-30 | 7.91e-01 | 0.2442 |
| 54505 | DHX29 | SYSMH4 | Human | Oral cavity | OSCC | 2.72e-02 | 1.29e-01 | 0.1226 |
| 54505 | DHX29 | SYSMH5 | Human | Oral cavity | OSCC | 1.45e-06 | 3.00e-01 | 0.0647 |
| 54505 | DHX29 | SYSMH6 | Human | Oral cavity | OSCC | 1.38e-11 | 3.95e-01 | 0.1275 |
| 54505 | DHX29 | P1_S1_AK | Human | Skin | AK | 2.59e-02 | 1.37e-01 | -0.3399 |
| 54505 | DHX29 | P2_S3_AK | Human | Skin | AK | 6.85e-03 | 1.22e-01 | -0.3287 |
| 54505 | DHX29 | P4_S8_cSCC | Human | Skin | cSCC | 2.08e-08 | 2.62e-01 | -0.3095 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
| GO:0006413110 | Esophagus | ESCC | translational initiation | 100/8552 | 118/18723 | 1.16e-18 | 1.25e-16 | 100 |
| GO:0006417111 | Esophagus | ESCC | regulation of translation | 304/8552 | 468/18723 | 1.53e-17 | 1.33e-15 | 304 |
| GO:0071826111 | Esophagus | ESCC | ribonucleoprotein complex subunit organization | 166/8552 | 227/18723 | 2.94e-17 | 2.42e-15 | 166 |
| GO:0022618111 | Esophagus | ESCC | ribonucleoprotein complex assembly | 159/8552 | 220/18723 | 8.19e-16 | 5.71e-14 | 159 |
| GO:0045727111 | Esophagus | ESCC | positive regulation of translation | 107/8552 | 136/18723 | 2.79e-15 | 1.68e-13 | 107 |
| GO:0034250111 | Esophagus | ESCC | positive regulation of cellular amide metabolic process | 123/8552 | 162/18723 | 3.32e-15 | 1.93e-13 | 123 |
| GO:000644617 | Esophagus | ESCC | regulation of translational initiation | 65/8552 | 79/18723 | 2.04e-11 | 7.07e-10 | 65 |
| GO:0002183110 | Esophagus | ESCC | cytoplasmic translational initiation | 32/8552 | 34/18723 | 2.18e-09 | 4.94e-08 | 32 |
| GO:0042255111 | Esophagus | ESCC | ribosome assembly | 50/8552 | 61/18723 | 5.66e-09 | 1.17e-07 | 50 |
| GO:00459483 | Esophagus | ESCC | positive regulation of translational initiation | 23/8552 | 30/18723 | 5.47e-04 | 3.00e-03 | 23 |
| GO:00017319 | Esophagus | ESCC | formation of translation preinitiation complex | 10/8552 | 11/18723 | 2.54e-03 | 1.08e-02 | 10 |
| GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| GO:004225412 | Liver | Cirrhotic | ribosome biogenesis | 154/4634 | 299/18723 | 1.18e-23 | 6.72e-21 | 154 |
| GO:000641312 | Liver | Cirrhotic | translational initiation | 76/4634 | 118/18723 | 8.36e-20 | 2.18e-17 | 76 |
| GO:007182612 | Liver | Cirrhotic | ribonucleoprotein complex subunit organization | 115/4634 | 227/18723 | 2.67e-17 | 3.63e-15 | 115 |
| GO:002261812 | Liver | Cirrhotic | ribonucleoprotein complex assembly | 112/4634 | 220/18723 | 4.35e-17 | 5.81e-15 | 112 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DHX29 | SNV | Missense_Mutation | novel | c.1207C>G | p.Pro403Ala | p.P403A | Q7Z478 | protein_coding | tolerated(0.41) | benign(0) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| DHX29 | SNV | Missense_Mutation | rs746293690 | c.1795A>G | p.Ser599Gly | p.S599G | Q7Z478 | protein_coding | tolerated(0.06) | probably_damaging(0.964) | TCGA-AN-A0XT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| DHX29 | SNV | Missense_Mutation | c.3761N>G | p.Ala1254Gly | p.A1254G | Q7Z478 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-BH-A1EV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| DHX29 | SNV | Missense_Mutation | c.1834N>C | p.Asp612His | p.D612H | Q7Z478 | protein_coding | deleterious(0) | possibly_damaging(0.78) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
| DHX29 | SNV | Missense_Mutation | c.1539N>C | p.Lys513Asn | p.K513N | Q7Z478 | protein_coding | tolerated(0.26) | benign(0.021) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| DHX29 | SNV | Missense_Mutation | novel | c.1033N>C | p.Glu345Gln | p.E345Q | Q7Z478 | protein_coding | deleterious(0.01) | probably_damaging(0.946) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| DHX29 | deletion | Frame_Shift_Del | novel | c.1065delN | p.Asp356IlefsTer9 | p.D356Ifs*9 | Q7Z478 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| DHX29 | SNV | Missense_Mutation | novel | c.2900A>G | p.Glu967Gly | p.E967G | Q7Z478 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DHX29 | SNV | Missense_Mutation | rs778194125 | c.2494C>T | p.Arg832Cys | p.R832C | Q7Z478 | protein_coding | deleterious(0) | possibly_damaging(0.719) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| DHX29 | SNV | Missense_Mutation | c.532G>A | p.Glu178Lys | p.E178K | Q7Z478 | protein_coding | tolerated(0.89) | benign(0.001) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |